340 related articles for article (PubMed ID: 27154483)
21. Predicting recurrence after unprovoked venous thromboembolism: prospective validation of the updated Vienna Prediction Model.
Tritschler T; Méan M; Limacher A; Rodondi N; Aujesky D
Blood; 2015 Oct; 126(16):1949-51. PubMed ID: 26341256
[TBL] [Abstract][Full Text] [Related]
22. Bleeding risk in patients with unprovoked venous thromboembolism: A critical appraisal of clinical prediction scores.
van Es N; Wells PS; Carrier M
Thromb Res; 2017 Apr; 152():52-60. PubMed ID: 28237891
[TBL] [Abstract][Full Text] [Related]
23. Extended therapy for primary and secondary prevention of venous thromboembolism.
Conway SE; Marcy TR
J Pharm Pract; 2010 Aug; 23(4):313-23. PubMed ID: 21507831
[TBL] [Abstract][Full Text] [Related]
24. Risk of recurrent venous thromboembolism in patients with HIV infection: A nationwide cohort study.
Rokx C; Borjas Howard JF; Smit C; Wit FW; Pieterman ED; Reiss P; Cannegieter SC; Lijfering WM; Meijer K; Bierman W; Tichelaar V; Rijnders BJA;
PLoS Med; 2020 May; 17(5):e1003101. PubMed ID: 32407386
[TBL] [Abstract][Full Text] [Related]
25. Effect of tailoring anticoagulant treatment duration by applying a recurrence risk prediction model in patients with venous thromboembolism compared to usual care: A randomized controlled trial.
Geersing GJ; Hendriksen JMT; Zuithoff NPA; Roes KC; Oudega R; Takada T; Schutgens REG; Moons KGM
PLoS Med; 2020 Jun; 17(6):e1003142. PubMed ID: 32589630
[TBL] [Abstract][Full Text] [Related]
26. Systematic review: D-dimer to predict recurrent disease after stopping anticoagulant therapy for unprovoked venous thromboembolism.
Verhovsek M; Douketis JD; Yi Q; Shrivastava S; Tait RC; Baglin T; Poli D; Lim W
Ann Intern Med; 2008 Oct; 149(7):481-90, W94. PubMed ID: 18838728
[TBL] [Abstract][Full Text] [Related]
27. D-dimer testing to select patients with a first unprovoked venous thromboembolism who can stop anticoagulant therapy: a cohort study.
Kearon C; Spencer FA; O'Keeffe D; Parpia S; Schulman S; Baglin T; Stevens SM; Kaatz S; Bauer KA; Douketis JD; Lentz SR; Kessler CM; Moll S; Connors JM; Ginsberg JS; Spadafora L; Julian JA;
Ann Intern Med; 2015 Jan; 162(1):27-34. PubMed ID: 25560712
[TBL] [Abstract][Full Text] [Related]
28. D-dimer levels and recurrence in patients with unprovoked VTE and a negative qualitative D-dimer test after treatment.
Kearon C; Parpia S; Spencer FA; Baglin T; Stevens SM; Bauer KA; Lentz SR; Kessler CM; Douketis JD; Moll S; Kaatz S; Schulman S; Connors JM; Ginsberg JS; Spadafora L; Liaw PC; Weitz JI; Julian JA
Thromb Res; 2016 Oct; 146():119-125. PubMed ID: 27354153
[TBL] [Abstract][Full Text] [Related]
29. A risk score for prediction of recurrence in patients with unprovoked venous thromboembolism (DAMOVES).
Franco Moreno AI; García Navarro MJ; Ortiz Sánchez J; Martín Díaz RM; Madroñal Cerezo E; de Ancos Aracil CL; Cabello Clotet N; Perales Fraile I; Gimeno García S; Montero Hernández C; Zapatero Gaviria A; Ruiz Giardín JM
Eur J Intern Med; 2016 Apr; 29():59-64. PubMed ID: 26775136
[TBL] [Abstract][Full Text] [Related]
30. Non-vitamin K antagonist oral anticoagulants for the prevention of recurrent venous thromboembolism.
Bauersachs R
Thromb Res; 2016 Aug; 144():12-20. PubMed ID: 27263046
[TBL] [Abstract][Full Text] [Related]
31. One-year adherence to warfarin treatment for venous thromboembolism in high-risk patients and its association with long-term risk of recurrent events.
Chen SY; Wu N; Gulseth M; LaMori J; Bookhart BK; Boulanger L; Fields L; Schein J
J Manag Care Pharm; 2013 May; 19(4):291-301. PubMed ID: 23627575
[TBL] [Abstract][Full Text] [Related]
32. Long-term risk of recurrent venous thromboembolism after a first contraceptive-related event: Data from REVERSE cohort study.
Aziz D; Skeith L; Rodger MA; Sabri E; Righini M; Kovacs MJ; Carrier M; Kahn SR; Wells PS; Anderson DR; Chagnon I; Solymoss S; Crowther MA; White RH; Le Gal G
J Thromb Haemost; 2021 Jun; 19(6):1526-1532. PubMed ID: 33724705
[TBL] [Abstract][Full Text] [Related]
33. Venous thromboembolism in cancer patients.
Deng A; Galanis T; Graham MG
Hosp Pract (1995); 2014 Dec; 42(5):24-33. PubMed ID: 25485915
[TBL] [Abstract][Full Text] [Related]
34. Models for predicting venous thromboembolism in ambulatory patients with lung cancer: a systematic review protocol.
Yan AR; Samarawickrema I; Naunton M; Peterson GM; Yip D; Mortazavi R
BMJ Open; 2021 Dec; 11(12):e055322. PubMed ID: 34853112
[TBL] [Abstract][Full Text] [Related]
35. Long-term risk of venous thrombosis after stopping anticoagulants for a first unprovoked event: A multi-national cohort.
Rodger MA; Scarvelis D; Kahn SR; Wells PS; Anderson DA; Chagnon I; Le Gal G; Gandara E; Solymoss S; Sabri E; Kovacs J; Kovacs MJ
Thromb Res; 2016 Jul; 143():152-8. PubMed ID: 27086275
[TBL] [Abstract][Full Text] [Related]
36. Aspirin for the prevention of recurrent venous thromboembolism: the INSPIRE collaboration.
Simes J; Becattini C; Agnelli G; Eikelboom JW; Kirby AC; Mister R; Prandoni P; Brighton TA;
Circulation; 2014 Sep; 130(13):1062-71. PubMed ID: 25156992
[TBL] [Abstract][Full Text] [Related]
37. Predicting recurrent venous thromboembolism in cancer: is it possible?
Kyrle PA
Thromb Res; 2014 May; 133 Suppl 2():S17-22. PubMed ID: 24862139
[TBL] [Abstract][Full Text] [Related]
38. Risk assessment models for venous thromboembolism in hospitalised adult patients: a systematic review.
Pandor A; Tonkins M; Goodacre S; Sworn K; Clowes M; Griffin XL; Holland M; Hunt BJ; de Wit K; Horner D
BMJ Open; 2021 Jul; 11(7):e045672. PubMed ID: 34326045
[TBL] [Abstract][Full Text] [Related]
39. Development of a clinical prediction rule for risk stratification of recurrent venous thromboembolism in patients with cancer-associated venous thromboembolism.
Louzada ML; Carrier M; Lazo-Langner A; Dao V; Kovacs MJ; Ramsay TO; Rodger MA; Zhang J; Lee AY; Meyer G; Wells PS
Circulation; 2012 Jul; 126(4):448-54. PubMed ID: 22679142
[TBL] [Abstract][Full Text] [Related]
40. Assessing the risk of venous thromboembolism (VTE) in ambulatory patients with cancer: Rationale and implementation of a pharmacist-led VTE risk assessment program in an ambulatory cancer centre.
Pelletier R
J Oncol Pharm Pract; 2021 Jun; 27(4):911-918. PubMed ID: 33757321
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
